Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted treatment for ALS.

Columnist Kristin Neva sometimes get overwhelmed by her increasing caregiver responsibilities, but it helps her to know she's not alone.

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

Mitochondrial genome mutations may be linked to ALS, per a study, opening the door for new ways to diagnosing and treating ...

Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS ...